The 7th International Conference On Clinical and Engineering Frontiers in Pediatric and Congenital Heart Disease

项目摘要和摘要 先天性心脏病(CHD)是导致出生缺陷婴儿死亡的主要原因， 在美国，1%的新生儿。冠心病的成功治疗为改善这些患者的生活质量提供了机会 个人因此而对社会有益。美国有100多万成年人患有冠心病。在那里的时候 在过去的几十年里，在应用工程学基础来理解和了解CHD方面取得了很大的进步， 还有更多的事情需要完成。为了帮助工程师和医生集中精力，第六届国际会议 儿科和先天性心脏病的临床和工程前沿，该项目提出的会议， 将汇集工程学和医学学科的顶尖专业人士，以促进合作 两个社区在冠心病治疗研究中的差异。同时，这次会议将作为一个 鼓励下一代工程师和科学家继续寻求治疗冠心病的平台。 通过将这两个小组结合在一起，就有机会推进当前的治疗，识别出- 研究缺陷并将工程学应用于帮助医生了解血流动力学和 疾病的机械方面，改进和开发诊断工具和技术，并改进 治疗计划。因此，关注冠心病的会议可以实现更好的治疗和 对这种与年龄相关的疾病的了解，这种疾病困扰着美国相当一部分人口和 随之而来的与CHD相关的医疗成本的降低，伴随着患者生活质量的提高。 会议将为参与生物医学的代表不足的团体的成员提供支持。 在儿科和先天性心脏病方面进行工程研究，从而坚持国家参与的目标 将代表不足的群体纳入STEM学科。本次会议还为以下方面提供了成功的榜样 国际组织和指导委员会的2名女性，她们已经建立了充满活力的 这一领域的研究计划和实验室。 这是本届会议的第六次迭代，我们寻求保持国际会议的连续性 儿科和先天性心脏病系列临床和工程前沿会议 有效地将从事尖端技术的工程学和医学领域的顶尖研究人员聚集在一起 对冠心病的研究。这是一个很好的论坛，可以交流想法和建立领导之间的合作 来自世界各地的研究人员。此外，会议还促进了新的研究人员参与到 通过青年调查员讲台演讲节目及其青年调查员海报大赛向现场宣传。 我们的会议目标是请求支持这一系列国际会议中的第六届 历来吸引美国两国的儿科和先天性心脏病的工程研究 以及国际参与者，为交流思想和研究提供了一个国际论坛。

Project Summary and Abstract Congenital heart disease (CHD) is the leading cause of death for infants born with birth defects and represents 1% of births in the US. Successful treatment of CHD offers opportunities to improve quality of life for these individuals with consequent benefit to society. Over 1 million adults in the US are living with CHD. While there has been much progress with applying engineering fundamentals to understand and CHD over the past decades, there remains more to accomplish. To help focus engineers and physicians, the 6th International Conference on Clinical and Engineering Frontiers in Pediatric and Congenital Heart Disease, the meeting this project proposes, will bring together leading professionals in both engineering and medical disciplines to foster collaboration between the 2 communities in the study of treatment of CHD. Concurrently, the conference will serve as a platform to encourage the next generation of engineers and scientists to continue pursuing treatments for CHD. By bringing together these 2 groups, there is an opportunity to advance current treatment, identify under- researched defects and bring engineering to bear as an aid to physicians in understanding hemodynamic and mechanical aspects of the disease, improving and developing diagnostic tools and technology, and improving treatment planning. Therefore, a conference focused on CHD can achieve improved treatment and understanding of this age-related disease that afflicts a significant segment of the US population and the consequent reduction of medical costs associated with CHD accompanied by an improved patient quality of life. The conference will offer support to members of underrepresented groups involved in biomedical engineering research in pediatric and congenital heart disease, thus upholding the national goal of engaging underrepresented groups into the STEM disciplines. This conference also provides successful role models for women, 2 who are on the international organizing and steering committee, who have established vibrant research programs and labs in this field. This is the 6th iteration of this conference and we seek to maintain the continuity of the International Conference on Clinical and Engineering Frontiers in Pediatric and Congenital Heart Disease series that effectively brings together leading researchers in engineering and medicine who are engaged in cutting edge research in CHD. This is an excellent forum to exchange ideas and build of collaborations between leading researchers from around the world. Moreover, the conference promotes new researchers becoming engaged in the field through the Young Investigator podium speaker program and its young investigator poster competition. Our conference objective is to request support for the 6th in this series of international conferences on the engineering research in pediatric and congenital heart disease which has historically attracted both USA and international participants, affording an international forum for exchange of ideas and research.